Xpert Perspectives from ACG 2014: Reporting on IBD

Program Description/Statement of Need

ACG is among the premier international meetings in gastroenterology. As such, an abundance of cutting-edge data that has a direct impact on current and future practice is presented and discussed; in fact, hundreds of abstracts were presented on inflammatory bowel disease alone. However, the information presented at this meeting often requires contextualization, extensive interpretation, and analysis before integration into clinical practice. After participating in this activity, participants will be better prepared to integrate the most recent advances in the diagnosis and management of inflammatory bowel disease into their day-to-day clinical practices.

Target Audience

This enduring activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the management of inflammatory bowel disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Describe the data presented at the American College of Gastroenterology 2014 Annual Meeting on epidemiology, diagnosis, and treatment of Crohn's disease and ulcerative colitis

Translate recent findings on the diagnosis and management of inflammatory bowel disease (IBD) into clinical practice

Credit Designation

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of Purdue University College of Pharmacy and the Gi Health Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Release Date: November 28, 2014
Expiration Date: November 28, 2015   
*This program has expired. CME credit is no longer available.

Disclosure

All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, Gi Health Foundation and Purdue University College of Pharmacy staff have no relationships to disclose.

Speaker Disclosures

Stephen Hanauer is a Consultant for AbbVie, Actavis, Ferring, Janssen Biotech, Inc., Pfizer, Prometheus Laboratories, Salix, sanofi-aventis, Shire, Takeda Pharmaceuticals International Inc., UCB. He has performed Clinical Research for AbbVie, Janssen Biotech, Inc., Pfizer, Prometheus Laboratories, sanofi-aventis, Takeda Pharmaceuticals International Inc., UCB and is a speaker for AbbVie, Janssen Biotech Inc., Takeda Pharmaceuticals International Inc.

Gary Lichtenstein is a Consultant for Actavis, Alaven, Elan, Ferring, Hospira, Janssen, Luitpold/American Regent, Millenium Pharmaceuticals, Pfizer Pharmaceuticals, Ono Pharmaceuticals, Prometheus Laboratories, Inc., Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, Takeda, UCB, Warner Chilcott. He has performed Clinical Research for Bristol-Myers Squibb, Ferring, Janssen, Prometheus Laboratories, Inc., Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, UBC, Warner Chilcott. He has also received honorarium from Ironwood, Luitpold/American Regent.

Raymond Cross is a Consultant for AbbVie, Janssen Biotech, Inc, Takeda Pharmaceuticals International, Inc. He has performed Clinical Research for AbbVie, Janssen Biotech, Inc, Shire. He has also received honorarium from AbbVie, Janssen Biotech, Inc, Takeda Pharmaceuticals International, Inc.